Harnessing human ADAR2 for RNA repair - Recoding a PINK1 mutation rescues mitophagy

Nucleic Acids Research

Volumn 45, Issue 5, 2017, Pages 2797-2808

  Wettengel, Jacqueline ^a   Reautschnig, Philipp ^a   Geisler, Sven ^b,c   Kahle, Philipp J ^b,c   Stafforst, Thorsten ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAR2 PROTEIN; ADENOSINE DEAMINASE; GUIDE RNA; PARKIN; PINK1 PROTEIN; UNCLASSIFIED DRUG; ADARB1 PROTEIN, HUMAN; MESSENGER RNA; PROTEIN KINASE; PTEN-INDUCED PUTATIVE KINASE; RNA BINDING PROTEIN; STOP CODON;

ARTICLE; CONTROLLED STUDY; DOUBLE STRANDED RNA BINDING DOMAIN; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE LOSS; GENE MUTATION; HELA CELL LINE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOPHAGY; NUCLEOTIDE BINDING SITE; PARKINSON DISEASE; PHENOTYPE; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA EDITING; RNA PROCESSING; RNA REPAIR; RNA SEQUENCE; RNA SYNTHESIS; STOP CODON; TRANSIENT TRANSFECTION; CHEMISTRY; GENETIC TRANSFECTION; GENETICS; GENOME; HEK293 CELL LINE; METABOLISM; POINT MUTATION;

ADENOSINE DEAMINASE; CODON, NONSENSE; GENOME; HEK293 CELLS; HELA CELLS; HUMANS; MITOCHONDRIAL DEGRADATION; POINT MUTATION; PROTEIN KINASES; RNA EDITING; RNA, GUIDE; RNA, MESSENGER; RNA-BINDING PROTEINS; TRANSFECTION;

EID: 85018319578     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkw911     Document Type: Article

References (57)

1. Nishikura, K. (2010) Functions and Regulation of RNA Editing by ADAR Deaminases. Annu. Rev. Biochem., 79, 321-349.
2. Kawahara, Y., Zinshteyn, B., Sethupathy, P., Iizasa, H., Hatzigeorgiou, A.G. and Nishikura, K. (2007) Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. Science, 315, 1137-1140.
3. Yang, W., Chendrimada, T.P., Wang, Q., Higuchi, M., Seeburg, P.H., Shiekhattar, R. and Nishikura, K. (2006) Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat. Struct. Mol. Biol., 13, 13-21.
4. Rueter, S.M., Dawson, T.R. and Emeson, R.B. (1999) Regulation of alternative splicing by RNA editing. Nature, 399, 75-80.
5. Rueter, S.M., Burns, C.M., Coode, S.A., Mookherjee, P. and Emeson, R.B. (1995) Glutamate receptor RNA editing in vitro by enzymatic conversion of adenosine to inosine. Science, 267, 1491-1494.
6. Melcher, T., Maas, S., Herb, A., Sprengel, R., Seeburg, P.H. and Higuchi, M. (1996) A mammalian RNA editing enzyme, Nature, 379, 460-464.
7. Bass, B.L. (2002) RNA editing by Adenosine Deaminases that act on RNA. Annu. Rev. Biochem., 71, 817-846.
8. Morabito, M.V., Abbas, A.I., Hood, J.L., Kesterson, R.A., Jacobs, M.M., Kump, D.S., Hachey, D.L., Roth, B.L. and Emeson, R.B. (2010) Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader-Willi syndrome. Neurobiol. Dis., 39, 169-180.
9. Maas, S., Kawahara, Y., Tamburro, K.M. and Nishikura, K. (2006) A-to-I RNA editing and human disease. RNA Biol., 3, 1-9.
10. Slotkin, W. and Nishikura, K. (2013) Adenosine-to-inosine RNA editing and human disease. Genome Med., 5, 105-118.
11. Silberberg, G., Lundin, D., Navon, R. and O?hman, M. (2012) Deregulation of the A-to-I RNA editing mechanism in psychiatric disorders. Hum. Mol. Genet., 21, 311-321.
12. Higuchi, M., Maas, S., Single, F.N., Hartner, J., Rozov, A., Burnashev, N., Feldmeyer, D., Sprengel, R. and Seeburg, P.H. (2000) Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature, 406, 78-81.
13. Rice, G.I., Kasher, P.R., Forte, G.M., Mannion, N.M., Greenwood, S.M., Szynkiewicz, M., Dickerson, J.E., Bhaskar, S.S., Zampini, M., Briggs, T.A. et al. (2012) Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat. Genet., 44, 1243-1248.
14. Zhang, X.J., He, P.P., Li, M., He, C.D., Yan, K.L., Cui, Y., Yang, S., Zhang, K.Y., Gao, M., Chen, J.J. et al. (2004) Seven novel mutations of the ADAR gene in Chinese families and sporadic patients with dyschromatosis symmetrica hereditaria (DSH). Hum. Mutat., 23, 629-630.
15. Hartner, J.C., Schmittwolf, C., Kispert, A., Muller, A.M., Higuchi, M. and Seeburg, P.H. (2004) Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. J. Biol. Chem., 279, 4894-4902.
16. Wang, Q., Miyakoda, M., Yang, W., Khillan, J., Stachura, D.L., Weiss, M.J. and Nishikura, K. (2004) Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J. Biol. Chem., 279, 4952-4961.
17. Liddicoat, B.J., Piskol, R., Chalk, A.M., Ramaswami, G., Higuchi, M., Hartner, J.C., Li, J.B., Seeburg, P.H. and Walkley, C.R. (2015) RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. Science, 349, 1115-1120.
18. Mannion, N.M., Greenwood, S.M., Young, R., Cox, S., Brindle, J., Read, D., Nellaker, C., Vesely, C., Ponting, C.P., McLaughlin, P.J. et al. (2014) The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep., 9, 1482-1494.
19. Chen, L., Li, Y., Lin, C.H., Chan, T.H., Chow, R.K., Song, Y., Liu, M., Yuan, Y.F., Fu, L., Kong, K.L. et al. (2013) Recoding RNA editing of antizyme inhibitor 1 predisposes to hepatocellular carcinoma. Nat. Med., 19, 209-216.
20. Shimokawa, T., Rahman, M.F., Tostar, U., Sonkoly, E., Ståhle, M., Pivarcsi, A., Palaniswamy, R. and Zaphiropoulos, P.G. (2013) RNA editing of the GLI1 transcription factor modulates the output of Hedgehog signaling. RNA Biol., 10, 321-333.
21. Gallo, A. (2013) RNA editing enters the limelight in cancer. Nat. Med., 19, 130-131.
22. Paz-Yaacov, N., Bazak, L., Buchumenski, I., Porath, H.T., Danan-Gotthold, M., Knisbacher, B.A., Eisenberg, E. and Levanon, E.Y. (2015) Elevated RNA Editing Activity Is a Major Contributor to Transcriptomic Diversity in Tumors. Cell Reports, 13, 267-276.
23. Han, L., Diao, L., Yu, S., Xu, X., Li, J., Zhang, R., Yang, Y., Werner, H.M., Eterovic, A.K., Yuan, Y., Li, J. et al. (2015) The genomic landscape and clinical relevance of A-to-I RNA editing in human cancers. Cancer Cell, 28, 515-528.
24. Picardi, E., Manzari, C., Mastropasqua, F., Aiello, I., D'Erchia, A.M. and Pesole, G. (2015) Profiling RNA editing in human tissues: Towards the inosinome Atlas. Sci. Rep., 5, 14941-14956.
25. Peng, Z., Cheng, Y., Tan, B.C., Kang, L., Tian, Z., Zhu, Y., Zhang, W., Liang, Y., Hu, X., Tan, X. et al. (2012) Comprehensive analysis of RNA-Seq data reveals extensive RNA editing in a human transcriptome. Nat. Biotech., 30, 253-260.
26. Bazak, L., Haviv, A., Barak, M., Jacob-Hirsch, J., Deng, P., Zhang, R., Isaacs, F.J., Rechavi, G., Li, J.B., Eisenberg, E. et al. (2014) A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes. Genome Res., 24, 365-376.
27. Ramaswami, G., Lin, W., Piskol, R., Tan, M.H., Davis, C. and Li, J.B. (2012) Accurate identification of human Alu and non-Alu RNA editing sites. Nat. Meth., 9, 579-581.
28. Stefl, R., Oberstrass, F.C., Hood, J.L., Jourdan, M., Zimmermann, M., Skrisovska, L., Maris, C., Peng, L., Hofr, C., Emeson, R.B. et al. (2010) The solution structure of the ADAR2 dsRBM-RNA complex reveals a sequence-specific readout of the minor groove. Cell, 143, 225-237.
29. Vogel, P. and Stafforst, T. (2014) Site-directed RNA editing with Antagomir Deaminases - A tool to study protein and RNA function. ChemMedChem, 9, 2021-2025.
30. Cox, D.B., Platt, R.J. and Zhang, F. (2015) Therapeutic genome editing: Prospects and challenges. Nat. Med., 21, 121-131.
31. Sehgal, A., Barros, S., Ivanciu, L., Cooley, B., Qin, J., Racie, T., Hettinger, J., Carioto, M., Jiang, Y., Brodsky, J. et al. (2015) An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat. Med., 21, 491-497.
32. Stern, M. and Alton, E.W.F.W. (2002) Use of liposomes in the treatment of cystic fibrosis. In: Albeda, SM (ed). Gene Therapy in Lung Disease: Lung Biology in Health and Disease. CRC Press, NY, Vol. 169, pp. 383-396.
33. Woolf, T.M., Chase, J.M. and Stinchcomb, D.T. (1995) Towards the therapeutic editing of mutated RNA sequences. Proc. Natl. Acad. Sci. U.S.A., 92, 8298-8302.
34. Stafforst, T. and Schneider, M.F. (2012) An RNA-Deaminase conjugate selectively repairs point mutations. Angew. Chem. Int. Ed. Engl., 51, 11166-11169.
35. Vogel, P., Schneider, M.F., Wettengel, J. and Stafforst, T. (2014) Improving site-directed RNA editing in vitro and in cell culture by chemical modification of the guideRNA. Angew. Chem. Int. Ed. Engl., 53, 6267-6271.
36. Montiel-Gonzalez, M. F., Guillermo, I., Yudowski, A. and Rosenthal, J. J. C. (2013) Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing. Proc. Natl. Acad. Sci. U.S.A., 110, 18285-18290.
37. Hanswillemenke, A., Kuzdere, T., Vogel, P., Jkely, G. and Stafforst, T. (2015) Site-directed RNA editing in vivo can be triggered by the light-driven assembly of an artificial riboprotein. J. Am. Chem. Soc., 137, 15875-15881.
38. World Health Organization (WHO). (2006) Neurological disorders: Public health challenges, Geneva, ISBN 9241563362.
39. Farrer, M.J. (2006) Genetics of Parkinson disease: Paradigm shifts and future prospects. Nat. Rev. Gen., 7, 306-318.
40. Valente, E.M., Abou-Sleiman, P.M., Caputo, V., Muqit, M.M., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A.R., Healy, D.G. et al. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science, 304, 1158-1160.
41. Geisler, S., Holmstrm, K.M., Skujat, D., Fiesel, F.C., Rothfuss, O.C., Kahle, P.J. and Springer, W. (2010) PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol., 12, 119-131.
42. Schneider, M.F., Wettengel, J., Hoffmann, P.C. and Stafforst, T. (2014) Optimal guideRNAs for re-directing deaminase activity of hADAR1 and hADAR2 in trans. Nucleic Acids Res., 42, e87.
43. Matthews, M.M., Thomas, J.M., Zheng, Y., Tran, K., Phelps, K.J., Scott, A.I., Havel, J., Fisher, A.J. and Beal, P.A. (2016) Structures of human ADAR2 bound to dsRNA reveal base-flipping mechanism and basis for site selectivity. Nat. Struct. Mol. Biol., 23, 426-433.
44. Persson, T., Hartmann, R. K. and Eckstein, F. (2002) Selection of hammerhead ribozyme variants with low Mg2+ requirement: Importance of stem-loop II. ChemBioChem, 3, 1066-1071.
45. Miyagishi, M. and Taira, K. (2002) U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. Nat. Biotech., 20, 497-500.
46. Lee, N. S., Dohjima, T., Bauer, G., Li, H., Li, M.J., Ehsani, A., Salvaterra, P. and Rossi, J.(2002) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotech., 20, 500-505.
47. Paul, C. P., Good, P. D., Winer, I. and Engelke, D. R. (2002) Effective expression of small interfering RNA in human cells. Nat. Biotech., 20, 505-508.
48. Daigle, N. and Ellenberg, J. (2007) LambdaN-GFP: An RNA reporter system for live-cell imaging. Nat. Methods, 4, 633-636.
49. Keryer-Bibens, C., Barreau, C. and Osborne, H. B. (2008) Tethering of proteins to RNAs by bacteriophage proteins. Biol. Cell, 100, 125-138.
50. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A. and Charpentier, E. (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337, 816-821.
51. Vives-Bauza, C., Zhou, C., Huang, Y., Cui, M., de Vries, R.L., Kim, J., May, J., Tocilescu, M.A., Liu, W., Ko, H.S. et al. (2010) PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc. Natl. Acad. Sci. U.S.A., 107, 378-383.
52. Eggington, J.M., Greene, T. and Bass, B.L. (2011) Predicting sites of ADAR editing in double-stranded RNA. Nat. Commun., 2, doi: 10.1038/ncomms1324.
53. Bennett, C.F. and Swayze, E.E. (2010) RNA targeting therapeutics: Molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol., 50, 259-293.
54. Kole, R., Krainer, A.R. and Altman, S. (2012) RNA therapeutics: Beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug. Discov., 11, 125-140.
55. Reautschnig, P., Vogel, P. and Stafforst, T. (2016) The notorious R.N.A. in the spotlight - drug or target for the treatment of disease. RNA Biol., doi: 10.1080/15476286.2016.1208323.
56. Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P.N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E. et al. (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med., 369, 819-829.
57. Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B.R., Sutherland, J.E., Hutabarat, R.M., Clausen, V.A., Karsten, V., Cehelsky, J. et al. (2014) Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial. Lancet., 383, 60-68.